1
|
Braun U, Hennig O, Forstner J, Gerhardt S, Deffaa M, Hirjak D, Deuschle M, Koopmann A, Wisch C, Fritz M, Ende G, Tost H, Schöfer P, Bischoff S, Janta M, Kiefer F, Schmahl C, Banaschewski T, Meyer-Lindenberg A. [Diagnosis and admission center : Establishment and evaluation of an integrated translational infrastructure for clinical psychiatric research]. DER NERVENARZT 2024; 95:254-261. [PMID: 38381168 PMCID: PMC10914871 DOI: 10.1007/s00115-024-01609-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Accepted: 12/14/2023] [Indexed: 02/22/2024]
Abstract
The routine in-depth characterization of patients with methods of clinical and scale-based examination, neuropsychology, based on biomaterials, and sensor-based information opens up transformative possibilities on the way to personalized diagnostics, treatment and prevention in psychiatry, psychotherapy, and psychosomatics. Effective integration of the additional temporal and logistical effort into everyday care as well as the acceptance by patients are critical to the success of such an approach but there is little evidence on this to date. We report here on the establishment of the Diagnosis and Admission Center (DAZ) at the Central Institute of Mental Health (ZI) in Mannheim. The DAZ is an outpatient unit upstream of other care structures for clinical and scientific phenotyping across diagnoses as a starting point for data-driven, individualized pathways to further treatment, diagnostics or research. We describe the functions, goals, and implementation of the newly created clinical scientific translational structure, provide an overview of the patient populations it has reached, and provide data on its acceptance. In this context, the close integration with downstream clinical processes enables a better coordinated and demand-oriented allocation. In addition, DAZ enables a faster start of disorder-specific diagnostics and treatment. Since its launch in April 2021 up to the end of 2022, 1021 patients underwent psychiatric evaluation at DAZ during a pilot phase. The patient sample corresponded to a representative sample from standard care and the newly established processes were regarded as helpful by patients. In summary, the DAZ uniquely combines the interests and needs of patient with the collection of scientifically relevant data.
Collapse
Affiliation(s)
- Urs Braun
- Zentralinstitut für Seelische Gesundheit, Medizinische Fakultät Mannheim, Universität Heidelberg, J5, 68159, Mannheim, Deutschland.
- Deutsches Zentrum für Psychische Gesundheit (DZPG), Mannheim-Heidelberg-Ulm, Deutschland.
| | - Oliver Hennig
- Zentralinstitut für Seelische Gesundheit, Medizinische Fakultät Mannheim, Universität Heidelberg, J5, 68159, Mannheim, Deutschland
| | - Johanna Forstner
- Zentralinstitut für Seelische Gesundheit, Medizinische Fakultät Mannheim, Universität Heidelberg, J5, 68159, Mannheim, Deutschland
| | - Sarah Gerhardt
- Zentralinstitut für Seelische Gesundheit, Medizinische Fakultät Mannheim, Universität Heidelberg, J5, 68159, Mannheim, Deutschland
| | - Mirjam Deffaa
- Zentralinstitut für Seelische Gesundheit, Medizinische Fakultät Mannheim, Universität Heidelberg, J5, 68159, Mannheim, Deutschland
| | - Dusan Hirjak
- Zentralinstitut für Seelische Gesundheit, Medizinische Fakultät Mannheim, Universität Heidelberg, J5, 68159, Mannheim, Deutschland
| | - Michael Deuschle
- Zentralinstitut für Seelische Gesundheit, Medizinische Fakultät Mannheim, Universität Heidelberg, J5, 68159, Mannheim, Deutschland
| | - Anne Koopmann
- Zentralinstitut für Seelische Gesundheit, Medizinische Fakultät Mannheim, Universität Heidelberg, J5, 68159, Mannheim, Deutschland
| | - Christian Wisch
- Zentralinstitut für Seelische Gesundheit, Medizinische Fakultät Mannheim, Universität Heidelberg, J5, 68159, Mannheim, Deutschland
| | - Melanie Fritz
- Zentralinstitut für Seelische Gesundheit, Medizinische Fakultät Mannheim, Universität Heidelberg, J5, 68159, Mannheim, Deutschland
| | - Gabriele Ende
- Zentralinstitut für Seelische Gesundheit, Medizinische Fakultät Mannheim, Universität Heidelberg, J5, 68159, Mannheim, Deutschland
- Deutsches Zentrum für Psychische Gesundheit (DZPG), Mannheim-Heidelberg-Ulm, Deutschland
| | - Heike Tost
- Zentralinstitut für Seelische Gesundheit, Medizinische Fakultät Mannheim, Universität Heidelberg, J5, 68159, Mannheim, Deutschland
- Deutsches Zentrum für Psychische Gesundheit (DZPG), Mannheim-Heidelberg-Ulm, Deutschland
| | - Peter Schöfer
- Zentralinstitut für Seelische Gesundheit, Medizinische Fakultät Mannheim, Universität Heidelberg, J5, 68159, Mannheim, Deutschland
| | - Stefan Bischoff
- Zentralinstitut für Seelische Gesundheit, Medizinische Fakultät Mannheim, Universität Heidelberg, J5, 68159, Mannheim, Deutschland
| | - Matthias Janta
- Zentralinstitut für Seelische Gesundheit, Medizinische Fakultät Mannheim, Universität Heidelberg, J5, 68159, Mannheim, Deutschland
| | - Falk Kiefer
- Zentralinstitut für Seelische Gesundheit, Medizinische Fakultät Mannheim, Universität Heidelberg, J5, 68159, Mannheim, Deutschland
- Deutsches Zentrum für Psychische Gesundheit (DZPG), Mannheim-Heidelberg-Ulm, Deutschland
| | - Christian Schmahl
- Zentralinstitut für Seelische Gesundheit, Medizinische Fakultät Mannheim, Universität Heidelberg, J5, 68159, Mannheim, Deutschland
- Deutsches Zentrum für Psychische Gesundheit (DZPG), Mannheim-Heidelberg-Ulm, Deutschland
| | - Tobias Banaschewski
- Zentralinstitut für Seelische Gesundheit, Medizinische Fakultät Mannheim, Universität Heidelberg, J5, 68159, Mannheim, Deutschland
- Deutsches Zentrum für Psychische Gesundheit (DZPG), Mannheim-Heidelberg-Ulm, Deutschland
| | - Andreas Meyer-Lindenberg
- Zentralinstitut für Seelische Gesundheit, Medizinische Fakultät Mannheim, Universität Heidelberg, J5, 68159, Mannheim, Deutschland
- Deutsches Zentrum für Psychische Gesundheit (DZPG), Mannheim-Heidelberg-Ulm, Deutschland
| |
Collapse
|
2
|
Pfennig A, Leopold K, Martini J, Boehme A, Lambert M, Stamm T, Bermpohl F, Reif A, Kittel-Schneider S, Juckel G, Fallgatter AJ, Kircher T, Jansen A, Pfeiffer S, Berndt C, Rottmann-Wolf M, Sauer C, Ritter P, Correll CU, Bechdolf A, Falkenberg I, Bauer M. Improving early recognition and intervention in people at increased risk for the development of bipolar disorder: study protocol of a prospective-longitudinal, naturalistic cohort study (Early-BipoLife). Int J Bipolar Disord 2020; 8:22. [PMID: 32607662 PMCID: PMC7326843 DOI: 10.1186/s40345-020-00183-4] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/17/2019] [Accepted: 03/07/2020] [Indexed: 12/12/2022] Open
Abstract
Background Bipolar disorders (BD) belong to the most severe mental disorders, characterized by an early onset and recurrent, severe episodes or a chronic course with poor psychosocial functioning in a proportion of patients. Many patients with BD experience substantial symptomatology months or even years before full BD manifestation. Adequate diagnosis and treatment is often delayed, which is associated with a worse outcome. This study aims to prospectively evaluate and improve early recognition and intervention strategies for persons at-risk for BD. Methods Early-BipoLife is a prospective-longitudinal cohort study of 1419 participants (aged 15–35 years) with at least five waves of assessment over a period of at least 2 years (baseline, 6, 12, 18 and 24 months). A research consortium of ten university and teaching hospitals across Germany conducts this study. The following risk groups (RGs) were recruited: RG I: help-seeking youth and young adults consulting early recognition centres/facilities presenting ≥ 1 of the proposed risk factors for BD, RG II: in-/outpatients with unipolar depressive syndrome, and RG III: in-/outpatients with attention-deficit/hyperactivity disorder (ADHD). The reference cohort was selected from the German representative IMAGEN cohort. Over the study period, the natural course of risk and resilience factors, early symptoms of BD and changes of symptom severity (including conversion to manifest BD) are observed. Psychometric properties of recently developed, structured instruments on potential risk factors for conversion to BD and subsyndromal symptomatology (Bipolar Prodrome Symptom Scale, Bipolar at-risk criteria, EPIbipolar) and biomarkers that potentially improve prediction are investigated. Moreover, actual treatment recommendations are monitored in the participating specialized services and compared to recently postulated clinical categorization and treatment guidance in the field of early BD. Discussion Findings from this study will contribute to an improved knowledge about the natural course of BD, from the onset of first noticeable symptoms (precursors) to fully developed BD, and about mechanisms of conversion from subthreshold to manifest BD. Moreover, these generated data will provide information for the development of evidence-based guidelines for early-targeted detection and preventive intervention for people at risk for BD.
Collapse
Affiliation(s)
- Andrea Pfennig
- Department of Psychiatry and Psychotherapy, Carl Gustav Carus University Hospital, Technische Universität Dresden, Fetscherstraße 74, 01307, Dresden, Germany.
| | - Karolina Leopold
- Department of Psychiatry, Psychotherapy and Psychosomatics, Vivantes Klinikum Am Urban, Berlin, Germany
| | - Julia Martini
- Department of Psychiatry and Psychotherapy, Carl Gustav Carus University Hospital, Technische Universität Dresden, Fetscherstraße 74, 01307, Dresden, Germany
| | - Anne Boehme
- Department of Psychiatry and Psychotherapy, Carl Gustav Carus University Hospital, Technische Universität Dresden, Fetscherstraße 74, 01307, Dresden, Germany
| | - Martin Lambert
- Department of Psychiatry and Psychotherapy, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Thomas Stamm
- Department of Psychiatry and Psychotherapy, Charité Universitätsmedizin Berlin, Berlin, Germany.,Department of Psychiatry, Psychotherapy and Psychosomatic, Medical School Brandenburg, Neuruppin, Germany
| | - Felix Bermpohl
- Department of Psychiatry and Psychotherapy, Charité Universitätsmedizin Berlin, Berlin, Germany
| | - Andreas Reif
- Department of Psychiatry, Psychosomatics and Psychotherapy, University Hospital Frankfurt, Frankfurt, Germany
| | - Sarah Kittel-Schneider
- Department of Psychiatry, Psychosomatics and Psychotherapy, University Hospital Frankfurt, Frankfurt, Germany
| | - Georg Juckel
- Department of Psychiatry and Psychotherapy, LWL-University Hospital Bochum, Ruhr-University Bochum, Bochum, Germany
| | - Andreas J Fallgatter
- Department of General Psychiatry and Psychotherapy, University Hospital Tübingen, Tübingen, Germany
| | - Tilo Kircher
- Department of Psychiatry and Psychotherapy, University Hospital Marburg, Marburg, Germany
| | - Andreas Jansen
- Department of Psychiatry and Psychotherapy, University Hospital Marburg, Marburg, Germany
| | - Steffi Pfeiffer
- Department of Psychiatry and Psychotherapy, Carl Gustav Carus University Hospital, Technische Universität Dresden, Fetscherstraße 74, 01307, Dresden, Germany
| | - Christina Berndt
- Department of Psychiatry and Psychotherapy, Carl Gustav Carus University Hospital, Technische Universität Dresden, Fetscherstraße 74, 01307, Dresden, Germany
| | - Maren Rottmann-Wolf
- Department of Psychiatry and Psychotherapy, Carl Gustav Carus University Hospital, Technische Universität Dresden, Fetscherstraße 74, 01307, Dresden, Germany
| | - Cathrin Sauer
- Department of Psychiatry and Psychotherapy, Carl Gustav Carus University Hospital, Technische Universität Dresden, Fetscherstraße 74, 01307, Dresden, Germany
| | - Philipp Ritter
- Department of Psychiatry and Psychotherapy, Carl Gustav Carus University Hospital, Technische Universität Dresden, Fetscherstraße 74, 01307, Dresden, Germany
| | - Christoph U Correll
- The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, The Zucker Hillside Hospital, Glen Oaks, NY, USA.,Department of Child- and Adolescent Psychiatry, Charité Universitätsmedizin Berlin, Berlin, Germany
| | - Andreas Bechdolf
- Department of Psychiatry, Psychotherapy and Psychosomatics, Vivantes Klinikum Am Urban, Berlin, Germany
| | - Irina Falkenberg
- Department of Psychiatry and Psychotherapy, University Hospital Marburg, Marburg, Germany
| | - Michael Bauer
- Department of Psychiatry and Psychotherapy, Carl Gustav Carus University Hospital, Technische Universität Dresden, Fetscherstraße 74, 01307, Dresden, Germany
| |
Collapse
|
3
|
Luckhaus C, Roosterman D, Juckel G. [Biobanking in Psychiatry]. FORTSCHRITTE DER NEUROLOGIE-PSYCHIATRIE 2020; 88:722-729. [PMID: 32542622 DOI: 10.1055/a-0832-8766] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Abstract
Medical biobanking is concerned with establishing and maintaining large-scale repositories of biological specimens combined with comprehensive archives of clinical and biographical information on donors. This aims for controlled high and consistent quality of specimens for future biomedical research. One major objective is to assemble multiple blood components for various types of biochemical analysis and experimentation including different isolated cell types. With proper cryo-conservation, blood-derived cells can be conserved and revitalized after thawing and employed as in-vitro cell models carrying specific biological traits of donors. Optimizing pre-analytical methods can reduce pre-analytical variance thereby reducing imprecision of analytical data. This is particularly valuable for multivariate analyses of biological systems ("omics") and biomarker research. Introducing biobanking to psychiatry carries the challenge of making diagnostic allocation more compatible with biological entities than is achieved with current diagnostic categories of ICD-10 or DSM-V. Diagnostic or transdiagnostic subgroups can be stratified using biologically anchored clinical criteria. An important ethical issue of biobanking is the need for broad consent by the donors for specimen use in not yet defined future research projects. The organizational, logistic and financial costs of establishing and maintaining a biobank are considerable, but seem well warranted in view of the gainable advances in biomedical research quality, translations and clinical applications.
Collapse
|
4
|
Budde M, Anderson‐Schmidt H, Gade K, Reich‐Erkelenz D, Adorjan K, Kalman JL, Senner F, Papiol S, Andlauer TFM, Comes AL, Schulte EC, Klöhn‐Saghatolislam F, Gryaznova A, Hake M, Bartholdi K, Flatau L, Reitt M, Quast S, Stegmaier S, Meyers M, Emons B, Haußleiter IS, Juckel G, Nieratschker V, Dannlowski U, Schaupp SK, Schmauß M, Zimmermann J, Reimer J, Schulz S, Wiltfang J, Reininghaus E, Anghelescu I, Arolt V, Baune BT, Konrad C, Thiel A, Fallgatter AJ, Figge C, von Hagen M, Koller M, Lang FU, Wigand ME, Becker T, Jäger M, Dietrich DE, Stierl S, Scherk H, Spitzer C, Folkerts H, Witt SH, Degenhardt F, Forstner AJ, Rietschel M, Nöthen MM, Falkai P, Schulze TG, Heilbronner U. A longitudinal approach to biological psychiatric research: The PsyCourse study. Am J Med Genet B Neuropsychiatr Genet 2019; 180:89-102. [PMID: 30070057 PMCID: PMC6585634 DOI: 10.1002/ajmg.b.32639] [Citation(s) in RCA: 41] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/15/2018] [Revised: 04/05/2018] [Accepted: 04/16/2018] [Indexed: 02/05/2023]
Abstract
In current diagnostic systems, schizophrenia and bipolar disorder are still conceptualized as distinct categorical entities. Recently, both clinical and genomic evidence have challenged this Kraepelinian dichotomy. There are only few longitudinal studies addressing potential overlaps between these conditions. Here, we present design and first results of the PsyCourse study (N = 891 individuals at baseline), an ongoing transdiagnostic study of the affective-to-psychotic continuum that combines longitudinal deep phenotyping and dimensional assessment of psychopathology with an extensive collection of biomaterial. To provide an initial characterization of the PsyCourse study sample, we compare two broad diagnostic groups defined by the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) classification system, that is, predominantly affective (n = 367 individuals) versus predominantly psychotic disorders (n = 524 individuals). Depressive, manic, and psychotic symptoms as well as global functioning over time were contrasted using linear mixed models. Furthermore, we explored the effects of polygenic risk scores for schizophrenia on diagnostic group membership and addressed their effects on nonparticipation in follow-up visits. While phenotypic results confirmed expected differences in current psychotic symptoms and global functioning, both manic and depressive symptoms did not vary between both groups after correction for multiple testing. Polygenic risk scores for schizophrenia significantly explained part of the variability of diagnostic group. The PsyCourse study presents a unique resource to research the complex relationships of psychopathology and biology in severe mental disorders not confined to traditional diagnostic boundaries and is open for collaborations.
Collapse
Affiliation(s)
- Monika Budde
- Institute of Psychiatric Phenomics and Genomics (IPPG)University Hospital, LMU MunichMunichGermany
| | - Heike Anderson‐Schmidt
- Institute of Psychiatric Phenomics and Genomics (IPPG)University Hospital, LMU MunichMunichGermany,Department of Psychiatry and PsychotherapyUniversity Medical Center GoettingenGoettingenGermany
| | - Katrin Gade
- Institute of Psychiatric Phenomics and Genomics (IPPG)University Hospital, LMU MunichMunichGermany,Department of Psychiatry and PsychotherapyUniversity Medical Center GoettingenGoettingenGermany
| | - Daniela Reich‐Erkelenz
- Institute of Psychiatric Phenomics and Genomics (IPPG)University Hospital, LMU MunichMunichGermany
| | - Kristina Adorjan
- Institute of Psychiatric Phenomics and Genomics (IPPG)University Hospital, LMU MunichMunichGermany,Department of Psychiatry and PsychotherapyUniversity Hospital, LMU MunichMunichGermany
| | - Janos L. Kalman
- Institute of Psychiatric Phenomics and Genomics (IPPG)University Hospital, LMU MunichMunichGermany,Department of Psychiatry and PsychotherapyUniversity Hospital, LMU MunichMunichGermany,International Max Planck Research School for Translational PsychiatryMax Planck Institute of PsychiatryMunichGermany
| | - Fanny Senner
- Institute of Psychiatric Phenomics and Genomics (IPPG)University Hospital, LMU MunichMunichGermany,Department of Psychiatry and PsychotherapyUniversity Hospital, LMU MunichMunichGermany
| | - Sergi Papiol
- Institute of Psychiatric Phenomics and Genomics (IPPG)University Hospital, LMU MunichMunichGermany,Department of Psychiatry and PsychotherapyUniversity Hospital, LMU MunichMunichGermany
| | - Till F. M. Andlauer
- Department of Translational PsychiatryMax Planck Institute of PsychiatryMunichGermany
| | - Ashley L. Comes
- Institute of Psychiatric Phenomics and Genomics (IPPG)University Hospital, LMU MunichMunichGermany,International Max Planck Research School for Translational PsychiatryMax Planck Institute of PsychiatryMunichGermany
| | - Eva C. Schulte
- Institute of Psychiatric Phenomics and Genomics (IPPG)University Hospital, LMU MunichMunichGermany,Department of Psychiatry and PsychotherapyUniversity Hospital, LMU MunichMunichGermany
| | - Farah Klöhn‐Saghatolislam
- Institute of Psychiatric Phenomics and Genomics (IPPG)University Hospital, LMU MunichMunichGermany,Department of Psychiatry and PsychotherapyUniversity Hospital, LMU MunichMunichGermany
| | - Anna Gryaznova
- Institute of Psychiatric Phenomics and Genomics (IPPG)University Hospital, LMU MunichMunichGermany
| | - Maria Hake
- Institute of Psychiatric Phenomics and Genomics (IPPG)University Hospital, LMU MunichMunichGermany
| | - Kim Bartholdi
- Institute of Psychiatric Phenomics and Genomics (IPPG)University Hospital, LMU MunichMunichGermany
| | - Laura Flatau
- Institute of Psychiatric Phenomics and Genomics (IPPG)University Hospital, LMU MunichMunichGermany
| | - Markus Reitt
- Department of Psychiatry and PsychotherapyUniversity Medical Center GoettingenGoettingenGermany
| | - Silke Quast
- Department of Psychiatry and PsychotherapyUniversity Medical Center GoettingenGoettingenGermany
| | - Sophia Stegmaier
- Department of Psychiatry and PsychotherapyUniversity of TübingenTübingenGermany
| | - Milena Meyers
- Department of PsychiatryRuhr University Bochum, LWL University HospitalBochumGermany
| | - Barbara Emons
- Department of PsychiatryRuhr University Bochum, LWL University HospitalBochumGermany
| | | | - Georg Juckel
- Department of PsychiatryRuhr University Bochum, LWL University HospitalBochumGermany
| | | | - Udo Dannlowski
- Department of PsychiatryUniversity of MünsterMünsterGermany
| | - Sabrina K. Schaupp
- Institute of Psychiatric Phenomics and Genomics (IPPG)University Hospital, LMU MunichMunichGermany,Department of Psychiatry and PsychotherapyBezirkskrankenhaus AugsburgAugsburgGermany
| | - Max Schmauß
- Department of Psychiatry and PsychotherapyBezirkskrankenhaus AugsburgAugsburgGermany
| | - Jörg Zimmermann
- Psychiatrieverbund Oldenburger Land gGmbH, Karl‐Jaspers‐KlinikBad ZwischenahnGermany
| | - Jens Reimer
- Department of PsychiatryKlinikum Bremen‐OstBremenGermany
| | - Sybille Schulz
- Department of PsychiatryKlinikum Bremen‐OstBremenGermany
| | - Jens Wiltfang
- Department of Psychiatry and PsychotherapyUniversity Medical Center GoettingenGoettingenGermany,German Center for Neurodegenerative Diseases (DZNE)GoettingenGermany,iBiMED, Medical Sciences DepartmentUniversity of AveiroAveiroPortugal
| | - Eva Reininghaus
- Department of Psychiatry and Psychotherapeutic MedicineResearch Unit for Bipolar Affective Disorder, Medical University of GrazGrazAustria
| | | | - Volker Arolt
- Department of PsychiatryUniversity of MünsterMünsterGermany
| | - Bernhard T. Baune
- Discipline of Psychiatry, Royal Adelaide HospitalAdelaide Medical School, The University of AdelaideAdelaideAustralia
| | - Carsten Konrad
- Department of Psychiatry and PsychotherapyAgaplesion DiakonieklinikumRotenburgGermany
| | - Andreas Thiel
- Department of Psychiatry and PsychotherapyAgaplesion DiakonieklinikumRotenburgGermany
| | | | - Christian Figge
- Karl‐Jaspers Clinic, European Medical School Oldenburg‐GroningenOldenburgGermany
| | - Martin von Hagen
- Clinic for Psychiatry and PsychotherapyClinical Center Werra‐MeißnerEschwegeGermany
| | | | - Fabian U. Lang
- Department of Psychiatry IIUlm University, Bezirkskrankenhaus GünzburgGünzburgGermany
| | - Moritz E. Wigand
- Department of Psychiatry IIUlm University, Bezirkskrankenhaus GünzburgGünzburgGermany
| | - Thomas Becker
- Department of Psychiatry IIUlm University, Bezirkskrankenhaus GünzburgGünzburgGermany
| | - Markus Jäger
- Department of Psychiatry IIUlm University, Bezirkskrankenhaus GünzburgGünzburgGermany
| | - Detlef E. Dietrich
- AMEOS Clinical Center HildesheimHildesheimGermany,Center for Systems Neuroscience (ZSN)HannoverGermany,Present address:
Burghof‐Klinik RintelnRintelnGermany
| | | | | | | | - Here Folkerts
- Department of Psychiatry, Psychotherapy and PsychosomaticsClinical Center WilhelmshavenWilhelmshavenGermany
| | - Stephanie H. Witt
- Department of Genetic Epidemiology in PsychiatryCentral Institute of Mental Health, Medical Faculty Mannheim, University of HeidelbergMannheimGermany
| | - Franziska Degenhardt
- Institute of Human Genetics, University of Bonn School of Medicine & University Hospital BonnBonnGermany,Department of GenomicsLife & Brain Center, University of BonnBonnGermany
| | - Andreas J. Forstner
- Institute of Human Genetics, University of Bonn School of Medicine & University Hospital BonnBonnGermany,Department of GenomicsLife & Brain Center, University of BonnBonnGermany,Human Genomics Research Group, Department of BiomedicineUniversity of BaselBaselSwitzerland,Department of Psychiatry (UPK)University of BaselBaselSwitzerland
| | - Marcella Rietschel
- Department of Genetic Epidemiology in PsychiatryCentral Institute of Mental Health, Medical Faculty Mannheim, University of HeidelbergMannheimGermany
| | - Markus M. Nöthen
- Institute of Human Genetics, University of Bonn School of Medicine & University Hospital BonnBonnGermany,Department of GenomicsLife & Brain Center, University of BonnBonnGermany
| | - Peter Falkai
- Department of Psychiatry and PsychotherapyUniversity Hospital, LMU MunichMunichGermany
| | - Thomas G. Schulze
- Institute of Psychiatric Phenomics and Genomics (IPPG)University Hospital, LMU MunichMunichGermany,Department of Psychiatry and PsychotherapyUniversity Medical Center GoettingenGoettingenGermany
| | - Urs Heilbronner
- Institute of Psychiatric Phenomics and Genomics (IPPG)University Hospital, LMU MunichMunichGermany
| |
Collapse
|
5
|
Wigand ME, Lang FU, Reichhardt L, Schulze TG, Walther S, Becker T, Jäger M. Severe clinical events in 100 patients with schizophrenia: a retrospective clinical description using a system-specific psychopathological approach. Nord J Psychiatry 2018; 72:1-8. [PMID: 28846054 DOI: 10.1080/08039488.2017.1368701] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Abstract
Catatonic states and numerous other severe clinical events can complicate the course of schizophrenia. Whether these severe courses are associated with particular system-specific symptom dimensions remain unclear. Aim is to assess the frequency of severe clinical events in a clinical population and to investigate the association of these events with sociodemographic data and system-specific psychopathology, combining qualitative and quantitative data. We performed a comprehensive retrospective description of a well-described and geographically stable sample of 100 patients with schizophrenia or schizoaffective disorder and linked severe clinical events with sociodemographic data at inclusion into the study (as indicators of social functioning) and symptoms at first admission, classified with the Bern Psychopathology Scale (BPS). We found 12 mentions of catatonic stupor or excitement, 45 of suicide attempts, 26 of suicidality, 18 of deliberate self-harm, 18 of self-threatening behaviour other than deliberate self-harm, 34 of violence against other persons, 18 of violence against objects and six of sexual harassment. Disinhibited language on first admission seemed to be a protective factor against suicidality and disinhibited motor behaviour seemed to predict self-threatening and violent behaviour. Catatonia and violence in particular seemed to be socially disabling. This exploratory study showed that the BPS is a promising instrument and might represent a system-specific approach in identifying patients at risk for severe sequelae of schizophrenia. This will have to be tested in future prospective studies.
Collapse
Affiliation(s)
- Moritz E Wigand
- a Department of Psychiatry and Psychotherapy II , Ulm University , Günzburg , Germany
| | - Fabian U Lang
- a Department of Psychiatry and Psychotherapy II , Ulm University , Günzburg , Germany.,b Medical Practice for Psychiatry and Psychotherapy Lang , Gersthofen , Germany
| | - Lea Reichhardt
- a Department of Psychiatry and Psychotherapy II , Ulm University , Günzburg , Germany
| | - Thomas G Schulze
- c Institute of Psychiatric Phenomics and Genomics , LMU München , Munich , Germany
| | - Sebastian Walther
- d Translational Research Center , University Hospital of Psychiatry , Bern , Switzerland
| | - Thomas Becker
- a Department of Psychiatry and Psychotherapy II , Ulm University , Günzburg , Germany
| | - Markus Jäger
- a Department of Psychiatry and Psychotherapy II , Ulm University , Günzburg , Germany.,e Department of Psychiatry, Psychosomatic and Psychotherapy , Bezirkskrankenhaus Kempten , Kempten , Germany
| |
Collapse
|
6
|
Wigand ME, Lang FU, Müller-Stierlin AS, Reichhardt L, Trif S, Schulze TG, Strik W, Becker T, Jäger M. Psychosis Is Mutable over Time: A Longitudinal Psychopathology Study. Psychopathology 2018. [PMID: 29539617 DOI: 10.1159/000486897] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Abstract
BACKGROUND A neurobiologically informed, system-specific psychopathological approach has been suggested for use in schizophrenia. However, to our knowledge, such an approach has not been used to prospectively describe the course of schizophrenia. SAMPLING AND METHODS We assessed psychopathology in a well-described sample of 100 patients with schizophrenia or schizoaffective disorder with the Bern Psychopathology Scale (BPS) at 6-month intervals for up to 18 months. The BPS groups symptoms into the 3 domains language, affectivity and motor behaviour; each domain is rated as being normal, inhibited or disinhibited. In addition, we collected qualitative psychopathological data in the form of case reports. RESULTS Forty-eight patients completed at least 2 assessments over the course of at least 1 year. Of these, 16 patients (33.3%) showed a bipolar course pattern (i.e., a switch from inhibited to disinhibited or vice versa) in 1 domain and 6 patients (12.5%) in more than 1 domain. Shifts from 1 dominant domain to another were seen frequently (n = 20, 41.7%), but shifts between 1 dominant domain and a combination of dominant domains were more common (n = 33, 68.8%). CONCLUSIONS The course of schizophrenia is heterogeneous and shows frequent changes in psychopathology. This should be taken into account in the communication with patients and in the research on underlying illness mechanisms and treatment. A major limitation of this study is the small sample size.
Collapse
Affiliation(s)
- Moritz E Wigand
- Department of Psychiatry II, Ulm University, Günzburg, Germany
| | - Fabian U Lang
- Department of Psychiatry II, Ulm University, Günzburg, Germany.,Medical Practice for Psychiatry and Psychotherapy Lang, Gersthofen, Germany
| | | | - Lea Reichhardt
- Department of Psychiatry II, Ulm University, Günzburg, Germany
| | - Silvana Trif
- Department of Psychiatry II, Ulm University, Günzburg, Germany
| | - Thomas G Schulze
- Institute of Psychiatric Phenomics and Genomics, LMU München, München, Germany
| | - Werner Strik
- Translational Research Center, University Hospital of Psychiatry, Bern, Switzerland
| | - Thomas Becker
- Department of Psychiatry II, Ulm University, Günzburg, Germany
| | - Markus Jäger
- Department of Psychiatry II, Ulm University, Günzburg, Germany.,Department of Psychiatry, Psychosomatics and Psychotherapy, Bezirkskrankenhaus Kempten, Kempten, Germany
| |
Collapse
|
7
|
Abstract
Schizophrenia is a devastating disease that arises on the background of genetic predisposition and environmental risk factors, such as early life stress (ELS). In this study, we show that ELS-induced schizophrenia-like phenotypes in mice correlate with a widespread increase of histone-deacetylase 1 (Hdac1) expression that is linked to altered DNA methylation. Hdac1 overexpression in neurons of the medial prefrontal cortex, but not in the dorsal or ventral hippocampus, mimics schizophrenia-like phenotypes induced by ELS. Systemic administration of an HDAC inhibitor rescues the detrimental effects of ELS when applied after the manifestation of disease phenotypes. In addition to the hippocampus and prefrontal cortex, mice subjected to ELS exhibit increased Hdac1 expression in blood. Moreover, Hdac1 levels are increased in blood samples from patients with schizophrenia who had encountered ELS, compared with patients without ELS experience. Our data suggest that HDAC1 inhibition should be considered as a therapeutic approach to treat schizophrenia.
Collapse
|
8
|
Abstract
Mental disorders are among the greatest medical and social challenges facing us. They can occur at all stages of life and are among the most important commonly occurring diseases. In Germany 28 % of the population suffer from a mental disorder every year, while the lifetime risk of suffering from a mental disorder is almost 50 %. Mental disorders cause great suffering for those affected and their social network. Quantitatively speaking, they can be considered to be among those diseases creating the greatest burden for society due to reduced productivity, absence from work and premature retirement. The Federal Ministry of Education and Research is funding a new research network from 2015 to 2019 with up to 35 million euros to investigate mental disorders in order to devise and develop better therapeutic measures and strategies for this population by means of basic and translational clinical research. This is the result of a competitive call for research proposals entitled research network for mental diseases. It is a nationwide network of nine consortia with up to ten psychiatric and clinical psychology partner institutions from largely university-based research facilities for adults and/or children and adolescents. Furthermore, three cross-consortia platform projects will seek to identify shared causes of diseases and new diagnostic modalities for anxiety disorders, attention deficit hyperactivity disorders (ADHS), autism, bipolar disorders, depression, schizophrenia and psychotic disorders as well as substance-related and addictive disorders. The spectrum of therapeutic approaches to be examined ranges from innovative pharmacological and psychotherapeutic treatment to novel brain stimulation procedures. In light of the enormous burden such diseases represent for society as a whole, a sustainable improvement in the financial support for those researching mental disorders seems essential. This network aims to become a nucleus for long overdue and sustained support for a German center for mental disorders.
Collapse
|
9
|
Wendland JR, Ehlers MD. Translating Neurogenomics Into New Medicines. Biol Psychiatry 2016; 79:650-6. [PMID: 26140822 DOI: 10.1016/j.biopsych.2015.04.027] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/01/2014] [Revised: 02/27/2015] [Accepted: 04/16/2015] [Indexed: 10/23/2022]
Abstract
Brain disorders remain one of the defining challenges of modern medicine and among the most poorly served with new therapeutics. Advances in human neurogenetics have begun to shed light on the genomic architecture of complex diseases of mood, cognition, brain development, and neurodegeneration. From genome-wide association studies to rare variants, these findings hold promise for defining the pathogenesis of brain disorders that have resisted simple molecular description. However, the path from genetics to new medicines is far from clear and can take decades, even for the most well-understood genetic disorders. In this review, we define three challenges for the field of neurogenetics that we believe must be addressed to translate human genetics efficiently into new therapeutics for brain disorders.
Collapse
Affiliation(s)
- Jens R Wendland
- PharmaTherapeutics Clinical Research, Worldwide Research and Development, Pfizer Inc., Cambridge, Massachusetts
| | - Michael D Ehlers
- Neuroscience Research Unit, Worldwide Research and Development, Pfizer Inc., Cambridge, Massachusetts.
| |
Collapse
|
10
|
McInnis MG, Greden JF. Longitudinal studies: An essential component for complex psychiatric disorders. Neurosci Res 2016; 102:4-12. [DOI: 10.1016/j.neures.2015.05.004] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2015] [Revised: 04/17/2015] [Accepted: 05/12/2015] [Indexed: 12/27/2022]
|
11
|
Lang FU, Müller-Stierlin AS, Walther S, Schulze TG, Becker T, Jäger M. Psychopathological Symptoms Assessed by a System-Specific Approach Are Related to Global Functioning in Schizophrenic Disorders. Psychopathology 2016; 49:77-82. [PMID: 27002327 DOI: 10.1159/000444505] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/11/2015] [Accepted: 02/03/2016] [Indexed: 11/19/2022]
Abstract
BACKGROUND By mostly using a positive-negative approach, several studies have identified factors that influence day-to-day functioning. We applied a different, system-specific approach to expand the knowledge of this issue. SAMPLING AND METHODS We recruited a sample of 100 inpatients with a DSM-IV diagnosis of schizophrenia or schizoaffective disorder. Psychopathological characteristics were assessed with the Bern Psychopathology Scale (BPS) and functional characteristics with the Global Assessment of Functioning (GAF) scale. Linear regression analyses were performed with the GAF score as the dependent variable and the global values of the BPS subscores as independent variables. The model was controlled for confounding variables. Spearman rank correlation analyses were used to identify associations between the relevant BPS subdomains and global functioning. RESULTS Higher absolute global values of the BPS domains language (px2009; = x2009;0.038) and motor behavior (px2009; = x2009;0.049) were significantly associated with lower GAF scores. These findings remained stable after adjusting for potential confounding variables. A statistically significant negative correlation was found between both qualitative symptoms (rx2009; = x2009;-0.273, px2009; = x2009;0.006) and indirect signs (rx2009; = x2009;-0.269, px2009; = x2009;0.007) of the language domain and GAF scores. Also, quantitative (rx2009; = x2009;-0.211, px2009; = x2009;0.035) and qualitative symptoms (rx2009; = x2009;-0.214, px2009; = x2009;0.033) in the motor behavior domain were associated with poorer functioning. CONCLUSIONS A system-specific approach can describe subgroups of patients with poor functioning. Identifying such subgroups could help to utilize targeted treatment opinions in a timely manner. Another goal of future research is to clarify the underlying neurobiological deficits.
Collapse
Affiliation(s)
- Fabian U Lang
- Department of Psychiatry and Psychotherapy II, Ulm University, Gx00FC;nzburg, Germany
| | | | | | | | | | | |
Collapse
|
12
|
|
13
|
Lang FU, Walther S, Stegmayer K, Anderson-Schmidt H, Schulze TG, Becker T, Jäger M. Subtyping schizophrenia: A comparison of positive/negative and system-specific approaches. Compr Psychiatry 2015; 61:115-21. [PMID: 26104431 DOI: 10.1016/j.comppsych.2015.05.014] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/18/2015] [Revised: 04/28/2015] [Accepted: 05/28/2015] [Indexed: 11/16/2022] Open
Abstract
BACKGROUND Schizophrenia is a heterogeneous disorder. Over the years, different approaches have been proposed to approach this heterogeneity by categorizing symptom patterns. The study aimed to compare positive/negative and system-specific approaches to subtyping. METHODS We used the Positive and Negative Syndrome Scale (PANSS) and Bern Psychopathology Scale (BPS), which consists of subscales for three domains (language, affect and motor behavior) that are hypothesized to be related to specific brain circuits, to assess cross-sectional psychopathological characteristics in a sample of 100 inpatients with schizophrenia spectrum disorders. We then categorized participants into positive/negative and system-specific subgroups to allow comparisons of the two approaches. RESULTS The analyses revealed correlations between the PANSS positive subscore and the BPS affective subscore (r=.446, p<.001) and between the PANSS negative subscore and the BPS motor behavior subscore (r=.227, p=.023). As regards the positive and negative subtype, more participants were classified as positive in the language-dominant subtype (30.3%) and affect-dominant subtype (30.3%), whereas more were classified as negative in the motor behavior-dominant subtype (44.4%). However, most patients met the criteria for the mixed subtype. CONCLUSIONS The results suggest that the positive/negative and system-specific approaches can be regarded as complementary. Future studies should examine both approaches in a longitudinal assessment of psychopathological symptoms and link them with qualitative-phenomenological approaches.
Collapse
Affiliation(s)
- F U Lang
- Department of Psychiatry and Psychotherapy II, Ulm University, Ulm, Germany.
| | - S Walther
- University Hospital of Psychiatry, Bern, Switzerland
| | - K Stegmayer
- University Hospital of Psychiatry, Bern, Switzerland
| | - H Anderson-Schmidt
- Institute of Psychiatric Phenomics and Genomics, Munich, Germany; Department of Psychiatry and Psychotherapy, Georg August University, Göttingen, Germany
| | - T G Schulze
- Institute of Psychiatric Phenomics and Genomics, Munich, Germany; Department of Psychiatry and Psychotherapy, Georg August University, Göttingen, Germany
| | - T Becker
- Department of Psychiatry and Psychotherapy II, Ulm University, Ulm, Germany
| | - M Jäger
- Department of Psychiatry and Psychotherapy II, Ulm University, Ulm, Germany
| |
Collapse
|
14
|
Buckow K, Quade M, Rienhoff O, Nussbeck SY. Changing requirements and resulting needs for IT-infrastructure for longitudinal research in the neurosciences. Neurosci Res 2014; 102:22-8. [PMID: 25152316 DOI: 10.1016/j.neures.2014.08.005] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2014] [Revised: 08/06/2014] [Accepted: 08/13/2014] [Indexed: 11/18/2022]
Abstract
The observation of growing "difficulties" in IT-infrastructures in neuroscience research during the last years led to a search for reasons and an analysis on how this phenomenon is reflected in the scientific literature. With a retrospective analysis of nine examples of multicenter research projects in the neurosciences and a literature review the observation was systematically analyzed. Results show that the rise in complexity mainly stems from two reasons: (1) more and more need for information on quality and context of research data (metadata) and (2) long-term requirements to handle the consent and identity/pseudonyms of study participants and biomaterials in relation to legal requirements. The combination of these two aspects together with very long study times and data evaluation periods are components of the subjectively perceived "difficulties". A direct consequence of this result is that big multicenter trials are becoming part of integrated research data environments and are not standing alone for themselves anymore. This drives up the resource needs regarding the IT-infrastructure in neuroscience research. In contrast to these findings, literature on this development is scarce and the problem probably underestimated.
Collapse
Affiliation(s)
- Karoline Buckow
- University Medical Center Göttingen, Department of Medical Informatics, Robert-Koch-Str. 40, 37075 Göttingen, Germany
| | - Matthias Quade
- University Medical Center Göttingen, Department of Medical Informatics, Robert-Koch-Str. 40, 37075 Göttingen, Germany
| | - Otto Rienhoff
- University Medical Center Göttingen, Department of Medical Informatics, Robert-Koch-Str. 40, 37075 Göttingen, Germany
| | - Sara Y Nussbeck
- University Medical Center Göttingen, Department of Medical Informatics, Robert-Koch-Str. 40, 37075 Göttingen, Germany.
| |
Collapse
|
15
|
Schmitt A, Falkai P. Therapeutic targets in major psychiatric disorders revisited. Eur Arch Psychiatry Clin Neurosci 2013; 263:619-20. [PMID: 24162800 DOI: 10.1007/s00406-013-0467-3] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Affiliation(s)
- Andrea Schmitt
- Department of Psychiatry and Psychotherapy, Ludwig-Maximilians-University Munich, Nußbaumstr. 7, 80336, Munich, Germany,
| | | |
Collapse
|